{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:21:40Z","timestamp":1780089700164,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.clinthera.2017.03.019","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:15:41Z","timestamp":1493079341000},"page":"993-1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece"],"prefix":"10.1016","volume":"39","author":[{"given":"Kostas","family":"Athanasakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Boubouchairopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Tarantilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Tsiantou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stathis","family":"Kontodimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kyriopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.03.019_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1684\/ejd.2009.0706","article-title":"Predisposing factors of actinic keratosis in a North-West German population","volume":"19","author":"Hensen","year":"2009","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib2","first-page":"S785","article-title":"Actinic keratoses: Prevalence, pathogenesis, presentation, and prevention. Adv","volume":"6","author":"Alam","year":"2006","journal-title":"Stud Med"},{"key":"10.1016\/j.clinthera.2017.03.019_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13555-015-0070-9","article-title":"Primary care review of actinic keratosis and its therapeutic options: a global perspective","volume":"5","author":"Chetty","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2017.03.019_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","article-title":"Epidemiology of actinic keratoses and squamous cell carcinoma","volume":"42","author":"Salasche","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00105-003-0543-0","article-title":"Actinic keratoses","volume":"54","author":"Babilas","year":"2003","journal-title":"Hautarzt"},{"key":"10.1016\/j.clinthera.2017.03.019_bib6","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0190-9622(88)70270-4","article-title":"Skin cancer in a Queensland population","volume":"19","author":"Green","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2013.134","article-title":"Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study","volume":"133","author":"Flohil","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13555-014-0049-y","article-title":"Actinic keratosis: rationale and management","volume":"4","author":"Dodds","year":"2014","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2017.03.019_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2133.1984.tb07458.x","article-title":"Relationship of solar keratosis and history of skin cancer to objective measures of actinic skin damage","volume":"110","author":"Holman","year":"1984","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2017.03.019_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2007.08267.x","article-title":"Pathology and pathobiology of actinic (solar) keratosis - an update","volume":"157","author":"Roewert-Huber","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12955-015-0295-4","article-title":"Health related quality of life in patients with actinic keratosis \u2013 an observational study of patients treated in dermatology specialist care in Denmark","volume":"13","author":"Tennvall","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2017.03.019_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00019053-200927060-00002","article-title":"Pharmacoeconomic considerations in treating actinic keratosis","volume":"27","author":"Neidecker","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.03.019_bib13","first-page":"184","article-title":"Cost for the treatment of actinic keratosis on the rise in Australia Version 2","volume":"3","author":"Perera","year":"2014","journal-title":"F1000Res"},{"key":"10.1016\/j.clinthera.2017.03.019_bib14","first-page":"1","article-title":"Ingenol mebutate:an introduction","volume":"17","author":"Fallen","year":"2012","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.clinthera.2017.03.019_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13555-012-0008-4","article-title":"The role of ingenol mebutate in the treatment of actinic keratoses","volume":"2","author":"Ali","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clinthera.2017.03.019_bib16","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis- International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.clindermatol.2013.05.007","article-title":"Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? facts and controversies","volume":"31","author":"Schmitt","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.14222","article-title":"Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomised controlled 12-month study","volume":"174","author":"Garbe","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.019_bib19","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.03.019_bib20","unstructured":"Lebwohl M. A randomized, parallel-group, double-blind, vehicle-controlled, multicenter study of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015%, in patients with actinic keratoses on the head. 22nd World Congress of Dermatology. Abstract P2181."},{"key":"10.1016\/j.clinthera.2017.03.019_bib21","unstructured":"Berman B. A multicenter, randomized, parallel-group, double-blind, vehicle-controlled evaluation of the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.015%, in patients with actinic keratoses on the head (face or scalp). 22nd World Congress of Dermatology. Abstract P2179."},{"key":"10.1016\/j.clinthera.2017.03.019_bib22","unstructured":"Anderson L. Multicenter, randomized, parallel-group, double-blind, vehicle-controlled phase III study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.05%, in patients with actinic keratoses on non-head locations. 22nd Congress of Dermatology. Abstract P2180."},{"key":"10.1016\/j.clinthera.2017.03.019_bib23","unstructured":"eMC. Summary of Product Characteristics: Solaraze\u2122 3%, gel. http:\/\/www.medicines.org.uk\/emc\/medicine\/21229. Accessed September 20, 2015."},{"key":"10.1016\/j.clinthera.2017.03.019_bib24","unstructured":"eMC. Summary of Product Characteristics: ALDARA 5% cream. http:\/\/www.medicines.org.uk\/emc\/medicine\/8. Accessed October 15, 2015."},{"key":"10.1016\/j.clinthera.2017.03.019_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","article-title":"Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model","volume":"28","author":"Wilson","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.03.019_bib26","unstructured":"Hellenic Association of Pharmaceutical Companies. Official pricing bulletins. https:\/\/www.sfee.gr\/pricing-bulletins-2\/?lang=en (In Greek). Accessed March 15, 2016."},{"key":"10.1016\/j.clinthera.2017.03.019_bib27","unstructured":"National Organization for Health Care Services Provision. Medical Procedures by Specialty. http:\/\/www.eopyy.gov.gr\/%CE%88%CE%B3%CE%B3%CF%81%CE%B1%CF%86%CE%B1%20%CE%95%CE%9F%CE%A0%CE%A5%CE%A5\/%CE%9F%CE%B4%CE%B7%CE%B3%CE%AF%CE%B5%CF%82%20-%20Manuals\/%CE%A0%CE%A1%CE%9F%CE%99%CE%9F%CE%9D%CE%A4%CE%91%20%CE%A3%CE%A5%CE%9C%CE%92%CE%91%CE%A3%CE%97%CE%A3%20%CE%91%CE%9D%CE%91%20%CE%95%CE%99%CE%94%CE%99%CE%9A%CE%9F%CE%A4%CE%97%CE%A4%CE%91.pdf (In Greek). Accessed March 15, 2016."},{"key":"10.1016\/j.clinthera.2017.03.019_bib28","doi-asserted-by":"crossref","first-page":"A423","DOI":"10.1016\/j.jval.2015.09.569","article-title":"Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain","volume":"18","author":"Ortega-Joaquin","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.03.019_bib29","doi-asserted-by":"crossref","first-page":"A423","DOI":"10.1016\/j.jval.2015.09.573","article-title":"Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% for Actinic Keratosis Treatment In Spain","volume":"18","author":"Elias","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.03.019_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12325-015-0211-7","article-title":"Cost-utility of first-line actinic keratosis treatments in Finland","volume":"32","author":"Soini","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2017.03.019_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10198-015-0679-8","article-title":"A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective","volume":"17","author":"Tolley","year":"2016","journal-title":"Eur J Health Econ"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817302011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817302011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T05:17:02Z","timestamp":1601961422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817302011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0149291817302011"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}